CFMS Conformis

Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022

Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022

BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023.

Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update.

Earnings Call and Webcast Details:

The webcast of the earnings call will be live at:

To attend by telephone, please use the information below for dial-in access.

  • Date and Time: March 1, 2023 – 4:30 p.m. Eastern Time
  • Please register for the call. You can register any time starting now through the call.
  • Link to register:
  • Registration in advance is encouraged.   As part of the registration process, you can choose to be provided with the dial-in and PIN or to use the automated “Call Me” feature.

Please visit the Investor Relations website at on March 1, 2023, to view the earnings release prior to the webcast and conference call.

The online archive of the webcast will be available on the company’s website at for 30 days.

About Conformis, Inc.

Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit . To receive future press releases via e-mail alerts, sign up at .

Contact

Investor Contact:

Investor Relations



(781) 374-5598



EN
23/01/2023

Underlying

CFMSConformis

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Conformis

 PRESS RELEASE
Free
CFMS CONFORMIS

restor3d Completes Acquisition of Conformis

restor3d Completes Acquisition of Conformis Combination Creates the World’s Preeminent Producer of Personalized Orthopedic Medical Devices, with Unmatched Additive Manufacturing Capabilities DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis’ common stock ceased tr...

September 5, 2023 1 EN
 PRESS RELEASE
Free
CFMS CONFORMIS

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conform...

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co., LLC (“Glass Lewis”), have each recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, und...

August 23, 2023 1 EN
 PRESS RELEASE
Free
CFMS CONFORMIS

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders ...

Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will a...

August 21, 2023 1 EN
 PRESS RELEASE
Free
CFMS CONFORMIS

Conformis Reports Second Quarter 2023 Financial Results

Conformis Reports Second Quarter 2023 Financial Results BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary Total revenue of $13.0 million, a decrease of 15% year-over-year on a reported and constant currency basis.Product revenue of $12.5 million, a decrease of 17% year-over-year on a reported and constant currency basis.Conformis hip system revenue ...

August 2, 2023 1 EN
 PRESS RELEASE
Free
CFMS CONFORMIS

Conformis Announces Definitive Agreement to be Acquired by restor3d fo...

Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash Combination creates a leading personalized 3D-printed orthopedic medical device company DURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ: CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approxi...

June 23, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch